Sélectionner la langue
HLA-DRA1*0101 & HLA-DRB1*1101 & CLIP (PVSKMRMATPLLMQA)
HLA-DRA1*0101 & HLA-DRB1*1101 & CLIP (PVSKMRMATPLLMQA) Liste de produits
- Attribut
Protein (1)
- Bibliothèque de produits
En ligne (1)
- Espèces
Human (1)
- Étiquette
His Tag & Avi Tag (1)
- Marqueur
Biotin-labeled (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HLP-H82Ed |  Human | HEK293 | Biotinylated Human HLA-DRA1*01:01&HLA-DRB1*11:01&CLIP (PVSKMRMATPLLMQA) Complex Protein (Monomer) |  |  |  Ajouter au panier |
Quantité totale1
- 1
HLA-DRA1*0101 & HLA-DRB1*1101 & CLIP (PVSKMRMATPLLMQA)Contexte de la molécule
HLA-DR is a isotype of MHC Class II responsible for presenting foreign antigens to the immune system's helper T-cells. The CLIP peptide, derived from the invariant chain, occupies the peptide-binding groove of the newly synthesized HLA-DR molecule to prevent it from loading irrelevant peptides inside the cell.
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Napabucasin | DP1; DP2A; BB-608; GB-201; BBI-608; BBI-608-DP1; BBI-608-DP2A; Z1HHM49K7O (UNII code) | Phase 3 Clinical | 1globe Biomedical Co Ltd, Pharmaceutics International Inc, Boston Biomedical Inc | Hematologic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Glioblastoma; Mesothelioma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms | Details |
| Nanocurcumin (Tehran University of Medical Sciences) | Phase 2 Clinical | Tehran University Of Medical Sciences | Neoplasms; Periapical Diseases | Details | |
| OPB-111077 | OPB-111077 | Phase 2 Clinical | Otsuka Pharmaceutical Co Ltd | Lymphoma, B-Cell; Solid tumours; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular | Details |
| Danvatirsen | AZD-9150; STAT-3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3Rx; IONIS-STAT3Rx; ISIS-STAT3-2.5Rx; IONIS-STAT3-2.5Rx | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Mismatch Repair Deficient Cancer; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Ascites; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
| HL-237 | HL-237 | Phase 2 Clinical | Hanlim Pharmaceutical Co Ltd | Arthritis, Rheumatoid | Details |
| M-1001 | M-1001; MEDICA-M1001 | Phase 2 Clinical | Syndromex | Dyslipidemias | Details |
| NT-219 | NT-219; NT219 | Phase 2 Clinical | TyrNovo Ltd | Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Neoplasm Metastasis | Details |
| Dimethylaminomicheliolide Fumarate | ACT-001 | Phase 2 Clinical | Tianjin Accendatech Technology Co Ltd | Glioblastoma; Small Cell Lung Carcinoma; Ganglioglioma; Central Nervous System Neoplasms; Optic Neuritis; Neuromyelitis Optica; Breast Neoplasms; Glioma; Brain metastases; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| C-188-9 | C188-9; C-188-9; TTI-101 | Phase 2 Clinical | Baylor College Of Medicine | Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Idiopathic Pulmonary Fibrosis; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| WP-1066 | WP-1066 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Medulloblastoma; Glioblastoma; Neoplasms; Brain Neoplasms; Brain metastases; Glioma; Melanoma | Details |
| YY-201 | YY-201; YY201 | Phase 1 Clinical | Shanghai Yuyao Biotechnology Co Ltd | Hematologic Neoplasms; Solid tumours; Prostatic Hyperplasia | Details |
| GLG-302 | GLG-302; GLG-805; S31-201; NSC-74859 | Phase 1 Clinical | H Lee Moffitt Cancer Center & Research Institute | Breast Neoplasms | Details |
| MOL-4239 | MOL-4239; WP-1220 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Psoriasis; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides | Details |
| Amcasertib/Napabucasin | Phase 1 Clinical | Boston Biomedical Inc | Neoplasms | Details | |
| ST-2286 | ST-2286; JW2286; JW-2286 | Phase 1 Clinical | C&C Research Laboratories | Solid tumours; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms | Details |
| KT-333 | KT-333; I-003 | Phase 1 Clinical | Kymera Therapeutics Inc | Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Lymphoid; Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic | Details |
| VVD-130850 | VVD-130850; BAY-3630914 | Phase 1 Clinical | Solid tumours | Details | |
| DCR-STAT3 | DCR-STAT3 | Phase 1 Clinical | Dicerna Pharmaceuticals Inc | Solid tumours; Neoplasms | Details |
| OPB-171775 | OPB-171775 | Phase 1 Clinical | Otsuka Pharmaceutical Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Golotimod | SCV-07 | Approved | Verta | Russian Federation | Hepatitis C; Mucositis | null | 2009-01-01 | Head and Neck Neoplasms; Hepatitis C; Mucositis; Stomatitis | Details | |
| Caffeic Acid | CABE | Approved | The University Of Texas MD Anderson Cancer Center, Moleculin Llc | Hemorrhage; Leukopenia; Thrombocytopenia | Details |
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques
Partager vers :